Powered by: Motilal Oswal

News

Aurobindo Pharma rises on getting EIR for Telangana manufacturing facility Aurobindo Pharma is currently trading at Rs. 864.95, up by 2.00 points or 0.23% from its previous closing of Rs. 862.95 on the BSE. The scrip opened at Rs. 864.30 and has touched a high and low of Rs. 868.30 and Rs. 858.75 respectively. So far 27476 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 887.20 on 14-Aug-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma rises on getting EIR for Telangana manufacturing facility
Aurobindo Pharma rises on getting EIR for Telangana manufacturing facility
Source: Accord Fintech
7/09/2023 12:51:48 PM
Stock Picks : Tata Consultancy Services Ltd And Aurobindo Pharma Ltd By ICICI Direct Tata Consultancy Services Ltd Buy Tata Consultancy Services Ltd @3419-3423; Target 3457.00; Stop Loss 3403.00   Aurobindo Pharma Ltd Buy Aurobindo Pharma Ltd @ 848-850; Target 859.80; Stop Loss 843.80   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Above views are of the author and...
Stock Picks : Tata Consultancy Services Ltd And Aurobindo Pharma Ltd By ICICI Direct
Stock Picks : Tata Consultancy Services Ltd And Aurobindo Pharma Ltd By ICICI Direct
Source: ICICI Direct
6/09/2023 10:56:31 AM
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services US/EU markets drive profitability Re-exploring restructuring of Eugia business * Aurobindo Pharma (ARBP) delivered operationally better-than-expected 1QFY24 performance, on the back of a healthy volume off-take in the US as well as the EU market. With improved outlook, ARBP has re-started the exercise to restructure the Eugia business and evaluate options to unlock the inherent value of its injectable business. * We raise our earnings estimate by 8%/7% for FY24/FY25, factoring a) su...
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
26/08/2023 12:56:15 PM
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services US/EU markets drive profitability Re-exploring restructuring of Eugia business * Aurobindo Pharma (ARBP) delivered operationally better-than-expected 1QFY24 performance, on the back of a healthy volume off-take in the US as well as the EU market. With improved outlook, ARBP has re-started the exercise to restructure the Eugia business and evaluate options to unlock the inherent value of its injectable business. * We raise our earnings estimate by 8%/7% for FY24/FY25, factoring a) superi...
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
Neutral Aurobindo Pharma Ltd For Target Rs.910 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
15/08/2023 11:10:34 AM
Aurobindo Pharma surges on reporting over 9% rise in Q1 consolidated net profit Aurobindo Pharma is currently trading at Rs. 885.45, up by 22.40 points or 2.60% from its previous closing of Rs. 863.05 on the BSE. The scrip opened at Rs. 864.75 and has touched a high and low of Rs. 887.20 and Rs. 851.10 respectively. So far 58531 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 887.20 on 14-Aug-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip s...
Aurobindo Pharma surges on reporting over 9% rise in Q1 consolidated net profit
Aurobindo Pharma surges on reporting over 9% rise in Q1 consolidated net profit
Source: Accord Fintech
14/08/2023 12:43:58 PM
Aurobindo Pharma surges as arm gets nod to manufacture, market Vancomycin Hydrochloride for injection Aurobindo Pharma surges as arm gets nod to manufacture, market Vancomycin Hydrochloride for injection Aug-07-2023   09:59 Hrs IST Aurobindo Pharma is currently trading at Rs. 863.90, up by 22.10 points or 2.63% from its previous closing of Rs. 841.80 on the BSE. The scrip opened at Rs. 843.25 and has touched a high and low of Rs. 864.45 and Rs. 839.70 respectively. So far 21288 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has tou...
Aurobindo Pharma surges as arm gets nod to manufacture, market Vancomycin Hydrochloride for injection
Aurobindo Pharma surges as arm gets nod to manufacture, market Vancomycin Hydrochloride for injection
Source: Accord Fintech
7/08/2023 10:16:07 AM
Aurobindo Pharma shines on incorporating Wholly Owned Step-down Subsidiary in Russia Aurobindo Pharma is currently trading at Rs. 826.00, up by 37.15 points or 4.71% from its previous closing of Rs. 788.85 on the BSE. The scrip opened at Rs. 798.00 and has touched a high and low of Rs. 829.50 and Rs. 792.10 respectively. So far 27014 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 829.50 on 27-Jul-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood ...
Aurobindo Pharma shines on incorporating Wholly Owned Step-down Subsidiary in Russia
Aurobindo Pharma shines on incorporating Wholly Owned Step-down Subsidiary in Russia
Source: Accord Fintech
27/07/2023 10:05:20 AM
Aurobindo Pharma gains after its arm gets USFDA`s final approval for Plerixafor Injection Aurobindo Pharma is currently trading at Rs. 788.65, up by 3.50 points or 0.45% from its previous closing of Rs. 785.15 on the BSE. The scrip opened at Rs. 775.45 and has touched a high and low of Rs. 791.40 and Rs. 775.45 respectively. So far 26313 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 791.85 on 24-Jul-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma gains after its arm gets USFDA`s final approval for Plerixafor Injection
Aurobindo Pharma gains after its arm gets USFDA`s final approval for Plerixafor Injection
Source: Accord Fintech
25/07/2023 3:47:47 PM
India`s Glenmark Life Sciences posts 25% rise in Q1 profit on API strength India's Glenmark Life Sciences reported a near-25% rise in its first-quarter profit on Friday, led by robust growth of its mainstay active pharmaceutical ingredients (API) business in domestic as well as U.S. and European markets. The Mumbai-based drug maker said profit stood at 1.35 billion rupees ($16.5 million) for the quarter ended June 30, compared with 1.09 billion rupees a year earlier. The company, spun off from Glenmark Pharmaceuticals in 2019 to focus on the API business, ...
India`s Glenmark Life Sciences posts 25% rise in Q1 profit on API strength
India`s Glenmark Life Sciences posts 25% rise in Q1 profit on API strength
Source: Reuters
21/07/2023 2:32:51 PM
Stock Picks : Aurobindo Pharma (AURPHA) Ltd and State Bank of India Ltd By ICICI Direct Aurobindo Pharma (AURPHA) Ltd Buy Aurobindo Pharma (AURPHA) Ltd @751-752; Target 763.00; Stop Loss 745.90   State Bank of India Ltd Buy State Bank of India Ltd @588-589; Target 597.00; Stop Loss 583.90       To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://www.tradebulls.in/disclaimer SEBI Registration number is INZ000171838  &nbs...
Stock Picks : Aurobindo Pharma (AURPHA) Ltd and State Bank of India Ltd By ICICI Direct
Stock Picks : Aurobindo Pharma (AURPHA) Ltd and State Bank of India Ltd By ICICI Direct
Source: ICICI Direct
19/07/2023 10:30:19 AM
Neutral Aurobindo Pharma Ltd For Target Rs.710 - Motilal Oswal Financial Services * Aurobindo Pharma (ARBP) has entered into an exclusive license agreement with BioFactura to commercialize a proposed biosimilar of Stelara (Ustekinumab). ? With this agreement, ARBP has fast-tracked its pipeline for biosimilar offerings. * The company is on track to build key levers of growth – a) accelerating the biosimilar pipeline, b) enhancing the ANDA pipeline comprising complex products, c) leveraging the PLI scheme, and d) expanding its China operations.  We value ARB...
Neutral Aurobindo Pharma Ltd For Target Rs.710 - Motilal Oswal Financial Services
Neutral Aurobindo Pharma Ltd For Target Rs.710 - Motilal Oswal Financial Services
Source: Yes Securities Ltd
10/07/2023 3:19:40 PM
Stock Picks : Mahindra&Mahindra Ltd and Aurobindo Pharma Ltd By ICICI Direct Mahindra&Mahindra Ltd Buy Mahindra&Mahindra Ltd @1472-1475; Target 1491.00; Stop Loss 1466.00 Aurobindo Pharma Ltd Buy Aurobindo Pharma Ltd @730-732; Target 742.00; Stop Loss 726.30     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631   Ab...
Stock Picks : Mahindra&Mahindra Ltd and Aurobindo Pharma Ltd By ICICI Direct
Stock Picks : Mahindra&Mahindra Ltd and Aurobindo Pharma Ltd By ICICI Direct
Source: ICICI Direct
6/07/2023 10:27:34 AM
Aurobindo Pharma trades higher as its group entity inks pact with Viatris Aurobindo Pharma is currently trading at Rs. 714.60, up by 2.25 points or 0.32% from its previous closing of Rs. 712.35 on the BSE. The scrip opened at Rs. 712.45 and has touched a high and low of Rs. 718.30 and Rs. 709.00 respectively. So far 20246 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 741.40 on 28-Jun-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma trades higher as its group entity inks pact with Viatris
Aurobindo Pharma trades higher as its group entity inks pact with Viatris
Source: Accord Fintech
4/07/2023 2:59:58 PM
Aurobindo Pharma surges as its arm inks voluntary license with Medicines Patent Pool Aurobindo Pharma is currently trading at Rs. 696.05, up by 24.85 points or 3.70% from its previous closing of Rs. 671.20 on the BSE. The scrip opened at Rs. 671.00 and has touched a high and low of Rs. 700.85 and Rs. 665.65 respectively. So far 66365 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 700.85 on 23-Jun-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood ...
Aurobindo Pharma surges as its arm inks voluntary license with Medicines Patent Pool
Aurobindo Pharma surges as its arm inks voluntary license with Medicines Patent Pool
Source: Accord Fintech
23/06/2023 3:11:17 PM
Neutral Aurobindo Pharma Ltd For Target Rs.600 - Motilal Oswal Financial Services Earnings decline for second consecutive year Levers in place to deliver growth over next two years * Aurobindo Pharma (ARBP) delivered a better-than-expected operating performance in 4QFY23, driven by healthy growth in the US/EU/ROW formulation and API segments. In addition to robust ANDA filings, ARBP continues to work toward building a niche portfolio in the biosimilar/ peptide space. Its ambitious Pen-G project is also on track for commercialization in FY25. * We raise our FY24/FY...
Neutral Aurobindo Pharma Ltd For Target Rs.600 - Motilal Oswal Financial Services
Neutral Aurobindo Pharma Ltd For Target Rs.600 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
6/06/2023 1:42:54 PM
Buy Aurobindo Pharma Ltd For Target Rs.600 - Motilal Oswal Financial Services Earnings decline for second consecutive year Levers in place to deliver growth over next two years * 4QFY23 sales grew 11% YoY to INR65b (est. INR63b). Total formulation sales rose 11% YoY to INR54.6b. US generics revenue grew 12% YoY to INR31b (flat YoY in CC terms at USD370m; 47% of sales). Growth Market sales jumped 51% YoY to INR6b (9% of sales). Europe formulation sales grew 8% YoY to INR16.6b (26% of sales). ARV sales declined 33% YoY to INR1.6b (2% of sales). API sales rose 11% Y...
Buy Aurobindo Pharma Ltd For Target Rs.600 - Motilal Oswal Financial Services
Buy Aurobindo Pharma Ltd For Target Rs.600 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
5/06/2023 4:20:44 PM
Aurobindo Pharma surges on getting nod to sell stake in Auro Vaccines Aurobindo Pharma is currently trading at Rs. 628.50, up by 17.30 points or 2.83% from its previous closing of Rs. 611.20 on the BSE. The scrip opened at Rs. 611.25 and has touched a high and low of Rs. 654.95 and Rs. 611.25 respectively. So far 136309 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 654.95 on 30-May-2023 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood...
Aurobindo Pharma surges on getting nod to sell stake in Auro Vaccines
Aurobindo Pharma surges on getting nod to sell stake in Auro Vaccines
Source: Accord Fintech
30/05/2023 11:51:43 AM
Stock Picks : Balrampur Chini Ltd and Aurobindo Pharma Ltd By ICICI Direct Balrampur Chini (BALCHI) Ltd Buy Balrampur Chini Ltd 385.00-386.00 CMP 384.60 ; Target 390.80; Stop Loss 382.20   Aurobindo Pharma Ltd Sell Aurobindo Pharma Ltd 605.00-608.00 CMP 599.80 ; Target 597.50; Stop Loss 612.70     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registrati...
Stock Picks : Balrampur Chini Ltd and Aurobindo Pharma Ltd By ICICI Direct
Stock Picks : Balrampur Chini Ltd and Aurobindo Pharma Ltd By ICICI Direct
Source: ICICI Direct
19/05/2023 10:17:27 AM
Aurobindo Pharma climbs on inking voluntary license with Medicines Patent Pool Aurobindo Pharma is currently trading at Rs. 517.60, up by 7.80 points or 1.53% from its previous closing of Rs. 509.80 on the BSE. The scrip opened at Rs. 511.55 and has touched a high and low of Rs. 520.50 and Rs. 510.85 respectively. So far 89496 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 714.60 on 06-Apr-2022 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma climbs on inking voluntary license with Medicines Patent Pool
Aurobindo Pharma climbs on inking voluntary license with Medicines Patent Pool
Source: Accord Fintech
31/03/2023 3:11:20 PM
Stock Picks : Aurobindo Pharma Ltd and Hindustan Unilever Ltd By ICICI Direct Aurobindo Pharma Ltd Aurobindo Pharma Ltd  @ 484-485 CMP486.00 Stop Loss 480.80 Target 491.30   Hindustan Unilever Ltd Hindustan Unilever Ltd @ 2479-2483 CMP 2485.10 Stop Loss 2461.40 Target 2514.00     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration num...
Stock Picks : Aurobindo Pharma Ltd and Hindustan Unilever Ltd By ICICI Direct
Stock Picks : Aurobindo Pharma Ltd and Hindustan Unilever Ltd By ICICI Direct
Source: ICICI Direct Ltd
24/03/2023 11:13:29 AM
Buy Aurobindo Pharma Ltd For Target Rs.650 - Yes Securities Improved margin outlook Result Synopsis Aurobindo Pharma reported a better quarter on back of some calm in the injectable as well as oral solids portfolio. Margin improved slightly QoQ though compared to last year base, price erosion in oral solids, increased freight costs still translated into persistent pressure on OPM. Aurobindo has indicated double digit growth in injectables in Q4 and Q1 FY24 which should assuage concern on the durability of the rebound in the near term. Oral so...
Buy Aurobindo Pharma Ltd For Target Rs.650 - Yes Securities
Buy Aurobindo Pharma Ltd For Target Rs.650 - Yes Securities
Source: Yes Securities Ltd
22/02/2023 12:01:40 PM
Aurobindo Pharma shines on getting nod to transfer of API Non-Antibiotic Division to Auro Pharma India Aurobindo Pharma is currently trading at Rs. 452.55, up by 11.85 points or 2.69% from its previous closing of Rs. 440.70 on the BSE. The scrip opened at Rs. 445.10 and has touched a high and low of Rs. 459.15 and Rs. 445.10 respectively. So far 49321 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 730.00 on 25-Mar-2022 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood ...
Aurobindo Pharma shines on getting nod to transfer of API Non-Antibiotic Division to Auro Pharma India
Aurobindo Pharma shines on getting nod to transfer of API Non-Antibiotic Division to Auro Pharma India
Source: Accord Fintech
10/02/2023 11:14:40 AM
Aurobindo Pharma gains as its arm receives USFDA`s approval for Diclofenac Sodium Topical Solution USP Aurobindo Pharma is currently trading at Rs. 423.00, up by 4.35 points or 1.04% from its previous closing of Rs. 418.65 on the BSE. The scrip opened at Rs. 419.10 and has touched a high and low of Rs. 424.15 and Rs. 415.35 respectively. So far 34505 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 730.00 on 25-Mar-2022 and a 52 week low of Rs. 397.30 on 03-Feb-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma gains as its arm receives USFDA`s approval for Diclofenac Sodium Topical Solution USP
Aurobindo Pharma gains as its arm receives USFDA`s approval for Diclofenac Sodium Topical Solution USP
Source: Accord Fintech
8/02/2023 11:57:40 AM
Aurobindo Pharma gains as its arm gets final approval from USFDA for Azacitidine Injection Aurobindo Pharma is currently trading at Rs. 442.50, up by 1.30 points or 0.29% from its previous closing of Rs. 441.20 on the BSE. The scrip opened at Rs. 444.75 and has touched a high and low of Rs. 445.00 and Rs. 440.10 respectively. So far 17669 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 742.25 on 11-Jan-2022 and a 52 week low of Rs. 429.30 on 02-Jan-2023. Last one week high and low of the scrip stood a...
Aurobindo Pharma gains as its arm gets final approval from USFDA for Azacitidine Injection
Aurobindo Pharma gains as its arm gets final approval from USFDA for Azacitidine Injection
Source: Accord Fintech
4/01/2023 12:01:37 PM
Aurobindo Pharma gains after its JV receives SEC recommendation for pneumococcal 15 valent vaccine Aurobindo Pharma is currently trading at Rs. 442.75, up by 5.50 points or 1.26% from its previous closing of Rs. 437.25 on the BSE. The scrip opened at Rs. 440.40 and has touched a high and low of Rs. 444.80 and Rs. 438.40 respectively. So far 102108 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 742.25 on 11-Jan-2022 and a 52 week low of Rs. 434.40 on 26-Dec-2022. Last one week high and low of the scrip stood ...
Aurobindo Pharma gains after its JV receives SEC recommendation for pneumococcal 15 valent vaccine
Aurobindo Pharma gains after its JV receives SEC recommendation for pneumococcal 15 valent vaccine
Source: Accord Fintech
27/12/2022 3:17:07 PM
Neutral Aurobindo Pharma Ltd For Target Rs.500 - Motilal Oswal Financial Services Price erosion in the US and higher OPEX impacts earning US outlook an area of worry; downgrade the stock to Neutral * ARBP delivered a 2QYF23 earnings miss, led by lower-than-expected US and ARV sales. Sales from Europe (EU) were stable YoY in CC terms, with a pickup in API sales. * We cut our FY23/FY24 earnings estimate by 18%/13% to factor in: a) reduced demand for Injectables, led by shelf stock adjustment, b) considerable price erosion in the base portfolio in the US segment, c) ...
Neutral Aurobindo Pharma Ltd For Target Rs.500 - Motilal Oswal Financial Services
Neutral Aurobindo Pharma Ltd For Target Rs.500 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
30/11/2022 2:37:38 PM
Key Stock News: Aurobindo Pharma, Air India, Lanco Amarkantak Power, Adani Enterprises, Wipro - ARETE Securities Aurobindo unit, Evive Biotech ink pact to sell CIN treatment product in US Aurobindo Pharma on Wednesday said its unit has entered into a licensing pact with Evive Biotech to commercialise Ryzneuta in the US market. The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is currently under late-stage review by the US Food and Drug Administration for chemotherapy-induced neutropenia (CIN).   Air India expands its US, Europe network with new non-stop flig...
Key Stock News: Aurobindo Pharma, Air India, Lanco Amarkantak Power, Adani Enterprises, Wipro - ARETE Securities
Key Stock News: Aurobindo Pharma, Air India, Lanco Amarkantak Power, Adani Enterprises, Wipro - ARETE Securities
Source: ARETE Securities Ltd
24/11/2022 10:01:02 AM
Aurobindo Pharma moves up on aiming to complete Pen G plant in Andhra Pradesh by March 2024 Aurobindo Pharma is currently trading at Rs. 463.60, up by 2.90 points or 0.63% from its previous closing of Rs. 460.70 on the BSE. The scrip opened at Rs. 461.05 and has touched a high and low of Rs. 464.85 and Rs. 461.05 respectively. So far 5545 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 742.25 on 11-Jan-2022 and a 52 week low of Rs. 457.20 on 14-Nov-2022. Last one week high and low of the scrip stood at...
Aurobindo Pharma moves up on aiming to complete Pen G plant in Andhra Pradesh by March 2024
Aurobindo Pharma moves up on aiming to complete Pen G plant in Andhra Pradesh by March 2024
Source: Accord Fintech
23/11/2022 11:23:59 AM
Indian drugmaker Aurobindo Pharma says its director arrested by enforcement directorate Aurobindo Pharma Ltd learnt Sarath Chandra Reddy, its whole time director, had been arrested by enforcement directorate, the Indian drugmaker said in an exchange filing on Thursday. The company, whose shares were down 6%, did not respond to Reuters' request for details on the arrest.
Indian drugmaker Aurobindo Pharma says its director arrested by enforcement directorate
Indian drugmaker Aurobindo Pharma says its director arrested by enforcement directorate
Source: Reuters
10/11/2022 2:25:55 PM
Aurobindo Pharma inches up as its arm receives EIR for Raleigh plant Aurobindo Pharma is currently trading at Rs. 522.00, up by 1.50 points or 0.29% from its previous closing of Rs. 520.50 on the BSE. The scrip opened at Rs. 518.05 and has touched a high and low of Rs. 529.45 and Rs. 516.60 respectively. So far 24603 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 751.45 on 04-Oct-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood a...
Aurobindo Pharma inches up as its arm receives EIR for Raleigh plant
Aurobindo Pharma inches up as its arm receives EIR for Raleigh plant
Source: Accord Fintech
23/09/2022 11:51:58 AM
Indian pharma industry likely to grow to $130 bn by 2030 The Indian pharma industry is expected to grow to $130 billion by 2030 and become the leading provider of medicines to the world, said Indian Pharmaceutical Alliance (IPA) Secretary General, Sudarshan Jain on Thursday. The Indian pharma industry is currently valued at $49 billion and is the third largest in the world. India supplied medicines to over 200 countries in the world, he said. He was speaking on the sidelines of three-day trade shows on laboratory technology and Pharma - machi...
Indian pharma industry likely to grow to $130 bn by 2030
Indian pharma industry likely to grow to $130 bn by 2030
Source: IANS
15/09/2022 5:10:15 PM
Aurobindo Pharma rises as its arm gets nod to expand mammalian cell culture manufacturing facility Aurobindo Pharma is currently trading at Rs. 539.40, up by 4.80 points or 0.90% from its previous closing of Rs. 534.60 on the BSE. The scrip opened at Rs. 536.50 and has touched a high and low of Rs. 542.90 and Rs. 536.10 respectively. So far 15536 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 767.45 on 15-Sep-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood a...
Aurobindo Pharma rises as its arm gets nod to expand mammalian cell culture manufacturing facility
Aurobindo Pharma rises as its arm gets nod to expand mammalian cell culture manufacturing facility
Source: Accord Fintech
5/09/2022 4:21:47 PM
Buy Aurobindo Pharma Limited For Target Rs.675 - Anand Rathi Share and Stock Brokers * AUROPHARMA has been under pressure since quiet some time but at this juncture its trading near its crucial support. * Previously the stock turned from this level and we saw a rally towards 820 APPROX. * On DAILY chart AUROPHARMA has bullish crab harmonic pattern which is looking lucrative. * Thus we advise traders to go long in the stock with a stop loss of 472 Buy Cochin Shipyard Ltd CMP: 540, STOP LOSS 472, TARGET 675     To Read Complete Report &am...
Buy Aurobindo Pharma Limited For Target Rs.675 - Anand Rathi Share and Stock Brokers
Buy Aurobindo Pharma Limited For Target Rs.675 - Anand Rathi Share and Stock Brokers
Source: Anand Rathi Share and Stock Brokers Ltd
29/08/2022 3:35:12 PM
Aurobindo Pharma jumps on acquiring 51% stake in GLS Pharma Aurobindo Pharma is currently trading at Rs. 583.95, up by 3.55 points or 0.61% from its previous closing of Rs. 580.40 on the BSE. The scrip opened at Rs. 579.45 and has touched a high and low of Rs. 586.35 and Rs. 566.60 respectively. So far 98079 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 767.45 on 15-Sep-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood a...
Aurobindo Pharma jumps on acquiring 51% stake in GLS Pharma
Aurobindo Pharma jumps on acquiring 51% stake in GLS Pharma
Source: Accord Fintech
18/08/2022 5:00:07 PM
Buy Aurobindo Pharma Ltd For Target Rs.750- Yes Securities Bottoming out of margin, valuation attractive Result Synopsis??????? Aurobindo Pharma reported a better US performance after several quarters of disappointment as US revenues rose 9% QoQ; price erosion seems to have moderated compared to 4Q while company catered to additional volume opportunities. Other segments like ARV, API and growth markets too rebounded barring Europe. Company underwent another round of input cost pressure as gross margin further compressed QoQ coupled with price e...
Buy Aurobindo Pharma Ltd For Target Rs.750- Yes Securities
Buy Aurobindo Pharma Ltd For Target Rs.750- Yes Securities
Source: Yes Securities Ltd
16/08/2022 3:47:10 PM
Aurobindo Pharma moves up as its arm receives USFDA`s approval for Vasopressin Injection Aurobindo Pharma is currently trading at Rs. 596.90, up by 3.60 points or 0.61% from its previous closing of Rs. 593.30 on the BSE. The scrip opened at Rs. 594.00 and has touched a high and low of Rs. 602.75 and Rs. 592.90 respectively. So far 29574 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 821.75 on 13-Aug-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood a...
Aurobindo Pharma moves up as its arm receives USFDA`s approval for Vasopressin Injection
Aurobindo Pharma moves up as its arm receives USFDA`s approval for Vasopressin Injection
Source: ACCCORD FINTECH
16/08/2022 10:22:57 AM
Key Stock News - Aditya Birla Health Insurance, Zerodha, Adani Group, Aurobindo Pharma, Bata India Ltd - ARETE Securities Key News ADIA to invest Rs 665 cr in Aditya Birla Health Insurance for 9.99% stake The boards of Aditya Birla Capital and Aditya Birla Health Insurance have approved a proposal of capital infusion to the tune of Rs 665 crore in the later from a subsidiary of Abu Dhabi Investment Authority (ADIA), the company said in a late-night statement. Aditya Birla Health Insurance is a 51:49 joint venture between Aditya Birla Capital Limited and Momentum Metropolitan Strategic Investments, a wh...
Key Stock News - Aditya Birla Health Insurance, Zerodha, Adani Group, Aurobindo Pharma, Bata India Ltd - ARETE Securities
Key Stock News - Aditya Birla Health Insurance, Zerodha, Adani Group, Aurobindo Pharma, Bata India Ltd - ARETE Securities
Source: ARETE Securities Ltd
12/08/2022 10:07:30 AM
Aurobindo Pharma gets 3 observations from USFDA for Andhra Pradesh unit US Food and Drug Administration (USFDA) has issued Form 483 with three observations after inspecting Aurobindo Pharma’s manufacturing facility at Pydibhimavaram in Andhra Pradesh. As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The Pydibhimavaram unit was classified as OAI (offic...
Aurobindo Pharma gets 3 observations from USFDA for Andhra Pradesh unit
Aurobindo Pharma gets 3 observations from USFDA for Andhra Pradesh unit
Source: Accord Fintech
3/08/2022 11:02:22 AM
Key Stock News - JSW group, Aurobindo Pharma, Adani Group, Tata Motors, Avenue Supermarts Ltd By ARETE Securities Key News JSW in talks with PEs, foreign banks for Mytrah Energy acquisition The JSW group has initiated talks with several private equity (PE) funds, including American investment management firm Apollo Global Management, to acquire its renewable power producer, Mytrah Energy (India) Pvt Ltd (MEIPL). The firm’s acquisition amount will be announced next month, banking sources said. The current enterprise valuation is $2 billion. JSW group’s JSW Energy has a target to add 15 g...
Key Stock News - JSW group, Aurobindo Pharma, Adani Group, Tata Motors, Avenue Supermarts Ltd By ARETE Securities
Key Stock News - JSW group, Aurobindo Pharma, Adani Group, Tata Motors, Avenue Supermarts Ltd By ARETE Securities
Source: ARETE Securities Ltd
11/07/2022 9:52:11 AM
Aurobindo Pharma trades higher as its arm gets USFDA nod for Triamcinolone Acetonide injectable suspension Aurobindo Pharma is currently trading at Rs. 542.05, up by 8.75 points or 1.64% from its previous closing of Rs. 533.30 on the BSE. The scrip opened at Rs. 531.45 and has touched a high and low of Rs. 543.45 and Rs. 530.00 respectively. So far 32014 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1003.85 on 06-Jul-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022. Last one week high and low of the scrip stood ...
Aurobindo Pharma trades higher as its arm gets USFDA nod for Triamcinolone Acetonide injectable suspension
Aurobindo Pharma trades higher as its arm gets USFDA nod for Triamcinolone Acetonide injectable suspension
Source: Accord Fintech
6/07/2022 3:43:48 PM
Aurobindo Pharma acquires business and certain assets of Veritaz Healthcare Aurobindo Pharma has completed the acquisition of business and certain assets of Veritaz Healthcare. Earlier, the company had received approval of the Board of Directors of the Company for the acquisition of the same. Veritaz operates in pharmaceutical industry in India and sells branded generic formulations and other health care related products. Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic ...
Aurobindo Pharma acquires business and certain assets of Veritaz Healthcare
Aurobindo Pharma acquires business and certain assets of Veritaz Healthcare
Source: Accord Fintech
5/07/2022 10:07:10 AM
Aurobindo Pharma jumps after its arm gets USFDA approval for Leuprolide Acetate injection Aurobindo Pharma is currently trading at Rs. 520.70, up by 4.35 points or 0.84% from its previous closing of Rs. 516.35 on the BSE. The scrip opened at Rs. 518.00 and has touched a high and low of Rs. 524.60 and Rs. 512.25 respectively. So far 75491 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1017.15 on 14-Jun-2021 and a 52 week low of Rs. 511.80 on 07-Jun-2022. Last one week high and low of the scrip stood ...
Aurobindo Pharma jumps after its arm gets USFDA approval for Leuprolide Acetate injection
Aurobindo Pharma jumps after its arm gets USFDA approval for Leuprolide Acetate injection
Source: Accord Fintech
8/06/2022 2:58:34 PM
Aurobindo Pharma declines on reporting 28% fall in Q4 consolidated net profit Aurobindo Pharma is currently trading at Rs. 532.75, down by 8.25 points or 1.52% from its previous closing of Rs. 541.00 on the BSE. The scrip opened at Rs. 541.20 and has touched a high and low of Rs. 546.50 and Rs. 527.40 respectively. So far 346162 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1017.15 on 14-Jun-2021 and a 52 week low of Rs. 514.50 on 25-May-2022. Last one week high and low of the scrip sto...
Aurobindo Pharma declines on reporting 28% fall in Q4 consolidated net profit
Aurobindo Pharma declines on reporting 28% fall in Q4 consolidated net profit
Source: Accord Fintech
2/06/2022 3:19:59 PM
Buy Aurobindo Pharma Ltd For Target Rs.770 - Yes Securities Margin up cycle on the cards Result Synopsis Aurobindo Pharma clocked a better gross margin performance QoQ as mix improved along with some price pass-through in external API sales. Management appeared surprised by the sequential 2.5% price erosion in US business and now expects such pricing pressure to persist for next 1-2 quarters. Albeit, higher injectable sales on a weak base of past 2 years should support margin. US injectable sales have gone nowhere since high watermark of ~US$270...
Buy Aurobindo Pharma Ltd For Target Rs.770 - Yes Securities
Buy Aurobindo Pharma Ltd For Target Rs.770 - Yes Securities
Source: Yes Securities Ltd
2/06/2022 12:35:16 PM
Buy Aurobindo Pharma Ltd For Target Rs. 640 - Motilal Oswal In line; see cost headwinds over the near term Work-in-progress to build a niche product pipeline * ARBP delivered an in line 4QFY22. Increased competitive intensity in US Generics and higher OPEX impacted profitability in 4QY22 on a YoY basis. * We cut our FY23/FY24 EPS estimate by 9%/12%, factoring in: a) a higher price erosion in the US base business, b) greater RM/logistics cost, and c) moderation in the EU/ARV business. We value ARBP at 12x 12M forward earnings to arrive at...
Buy Aurobindo Pharma Ltd For Target Rs. 640 - Motilal Oswal
Buy Aurobindo Pharma Ltd For Target Rs. 640 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
1/06/2022 12:44:07 PM
Aurobindo Pharma Q4 net profit down 8.07% at Rs 802.16 cr The company reported standalone net profit of Rs 802.16 crore for the quarter ended March 31, 2022 as compared to Rs 872.58 crore in the same period last year, registering a year-on-year decline of 8.07 per cent. Net revenue of the company declined substantially by 29.87 per cent at Rs 2,877.83 crore in January-March quarter of this fiscal as against Rs 4,103.61 crore in the corresponding period last year. During January-March quarter, operating expenses dropped by 24.15 per cent to Rs 2,3...
Aurobindo Pharma Q4 net profit down 8.07% at Rs 802.16 cr
Aurobindo Pharma Q4 net profit down 8.07% at Rs 802.16 cr
Source: Dion Global Solutions Ltd
31/05/2022 12:09:22 PM
Aurobindo Pharma surges as its arm gets USFDA’s final approval for Pemetrexed for Injection Aurobindo Pharma is currently trading at Rs. 528.45, up by 5.30 points or 1.01% from its previous closing of Rs. 523.15 on the BSE. The scrip opened at Rs. 531.15 and has touched a high and low of Rs. 531.30 and Rs. 518.30 respectively. So far 77248 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1043.00 on 26-May-2021 and a 52 week low of Rs. 514.50 on 25-May-2022. Last one week high and low of the scrip stood ...
Aurobindo Pharma surges as its arm gets USFDA’s final approval for Pemetrexed for Injection
Aurobindo Pharma surges as its arm gets USFDA’s final approval for Pemetrexed for Injection
Source: Accord Fintech
26/05/2022 2:06:55 PM
Stock Picks - Hindustan Unilever​​​​​​​ Ltd and Aurobindo Pharma Ltd By ICICI Direct Hindustan Unilever Ltd Buy Hindustan Unilever​​​​​​​ Ltd @ 2181.00-2183.00 CMP 2183.70 Stop Loss 2160.30 Target 2203.60/2225.00   Aurobindo Pharma Ltd Sell Aurobindo Pharma​​​​​​​ Ltd @ 602.00-604.00 CMP 604.10 Stop Loss 609.20 Target 597.2/590.60   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Discla...
Stock Picks - Hindustan Unilever​​​​​​​ Ltd and Aurobindo Pharma Ltd By ICICI Direct
Stock Picks - Hindustan Unilever​​​​​​​ Ltd and Aurobindo Pharma Ltd By ICICI Direct
Source: ICICI Direct
11/05/2022 12:15:14 PM